Vanda Pharmaceuticals Inc. - Common Stock (VNDA)

FDA denies Vanda's Tradipitant application for gastroparesis, urging new trials for efficacy and safety. Vanda disputes the agency's review process.

HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product portfolio, and growth in neurology.

A regulator's decision drained the market's enthusiasm for the company.

Future Pak wants Vanda, but Vanda doesn't want Future Pak.

The FDA rejected Vanda Pharmaceuticals' new drug application for tradipitant to treat gastroparesis, citing the need for more studies despite delays in its review process. Vanda argues the drug meets efficacy standards and plans to continue pursuing approval.

Vanda Pharmaceuticals shares decline as Future Pak withdraws acquisition offer following Vanda's rejection and lack of response.

Cycle Pharmaceuticals wants to acquire Vanda Pharmaceuticals for $8 per share, or $466 million. Cycle focuses on rare neurological conditions.

Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning!

VNDA stock results show that Vanda Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact."

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21. The S&P 500 also fell, dropping, 0.34% to 5,034.17.

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.